InvestSMART

TrivarX Ltd (ASX:TRI)

ALERT: Price-sensitive ASX Announcement for TRI
Current share price for TRI : $0.010 -0.019 (-64.91%)+
Announcement
Release
22 May 2026 9:36AM
Price at Release
$0.029
Full Release
download
Summary
TrivarX Limited has announced the engagement of Beyond Drug Development, a specialist Contract Research Organisation (CRO), to advance the Phase 1 safety trial of its proprietary MRI-based functional imaging platform, Stabl-Im. This trial will focus on assessing the safety and tolerability of Stabl-Im in healthy human volunteers, leveraging the expertise of Beyond in early-phase clinical development and regulatory strategy. The engagement marks a critical milestone in the broader strategy to advance Stabl-Im toward Phase 2 efficacy studies and commercialisation. TrivarX is aiming to commence the Phase 1 safety study during the second half of the 2026 calendar year, highlighting the platform's potential to provide early and meaningful insights into tumor activity and treatment response. The CEO, Dr. Danielle Meyrick, emphasized the strategic relevance of this partnership in positioning TrivarX for future clinical developments.
Key Points
  • TrivarX Limited engages Beyond Drug Development to progress the Phase 1 safety trial for Stabl-Im.
  • Stabl-Im is a proprietary MRI-based imaging platform designed to visualize tumor activity without radioactive tracers.
  • The Phase 1 trial will evaluate the safety and tolerability of Stabl-Im in healthy human volunteers.
  • Beyond Drug Development brings extensive expertise in early-phase clinical development and regulatory strategy.
  • The engagement is a significant milestone in advancing Stabl-Im toward Phase 2 studies and broader oncology applications.
  • TrivarX targets commencement of the Phase 1 safety study in the second half of the calendar year 2026.
  • Dr. Danielle Meyrick, CEO of TrivarX, highlights the strategic importance of the collaboration with Beyond Drug Development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.